Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001213900-23-027133
Filing Date
2023-04-04
Accepted
2023-04-04 16:30:18
Documents
15
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO FORM 10-K f10k2022a1_pasitheathera.htm   iXBRL 10-K/A 123867
2 CERTIFICATION f10k2022a1ex31-1_pasithea.htm EX-31.1 11375
3 CERTIFICATION f10k2022a1ex31-2_pasithea.htm EX-31.2 11383
  Complete submission text file 0001213900-23-027133.txt   387289

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ktta-20221231.xsd EX-101.SCH 3273
5 XBRL DEFINITION FILE ktta-20221231_def.xml EX-101.DEF 16943
6 XBRL LABEL FILE ktta-20221231_lab.xml EX-101.LAB 34780
7 XBRL PRESENTATION FILE ktta-20221231_pre.xml EX-101.PRE 18002
9 EXTRACTED XBRL INSTANCE DOCUMENT f10k2022a1_pasitheathera_htm.xml XML 4609
Mailing Address 2110 NARCISSUS CT VENICE CA 90291
Business Address 2110 NARCISSUS CT VENICE CA 90291 8184226172
Pasithea Therapeutics Corp. (Filer) CIK: 0001841330 (see all company filings)

EIN.: 851591963 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-40804 | Film No.: 23798215
SIC: 2834 Pharmaceutical Preparations